335 related articles for article (PubMed ID: 28266092)
21. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.
Lin L; Parra MM; Sierra VY; Cespedes AS; Granados MA; Luque A; Damaso S; Castrejon Alba MM; Romano-Mazzotti L; Struyf F
Pediatr Infect Dis J; 2018 Apr; 37(4):e93-e102. PubMed ID: 29424799
[TBL] [Abstract][Full Text] [Related]
22. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.
Schwarz TF; Spaczynski M; Schneider A; Wysocki J; Galaj A; Schulze K; Poncelet SM; Catteau G; Thomas F; Descamps D
Hum Vaccin; 2011 Sep; 7(9):958-65. PubMed ID: 21892005
[TBL] [Abstract][Full Text] [Related]
23. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
[TBL] [Abstract][Full Text] [Related]
24. Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020.
Wu Q; Qian M; Welby S; Guignard A; Rosillon D; Gopala K; Xu Y; Liu K; He Y; Jiang N; Tan Q; Xie J; Zhu T; Wang Q; Pan Y; Zeng R; Yang J; Zhao X; Zhou M; Navarro-Torné A; Yu H; Borys D
Hum Vaccin Immunother; 2023 Dec; 19(3):2283912. PubMed ID: 38038626
[TBL] [Abstract][Full Text] [Related]
25. Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine.
Angelo MG; Taylor S; Struyf F; Tavares Da Silva F; Arellano F; David MP; Dubin G; Rosillon D; Baril L
Expert Rev Vaccines; 2014 Nov; 13(11):1297-306. PubMed ID: 25219284
[TBL] [Abstract][Full Text] [Related]
26. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.
Angelo MG; Zima J; Tavares Da Silva F; Baril L; Arellano F
Pharmacoepidemiol Drug Saf; 2014 May; 23(5):456-65. PubMed ID: 24644078
[TBL] [Abstract][Full Text] [Related]
27. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
[TBL] [Abstract][Full Text] [Related]
28. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older.
Dos Santos G; Devadiga R; Kim CS; Bang J
Drug Saf; 2024 Apr; 47(4):365-375. PubMed ID: 38483767
[TBL] [Abstract][Full Text] [Related]
29. Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16-26 years in Chongqing, China.
Zhang YY; Xu JW; Liu Y; Qiu W; Bai PN; Zeng Y; Wang Q
Hum Vaccin Immunother; 2023 Dec; 19(3):2281700. PubMed ID: 38112061
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh.
Khatun S; Akram Hussain SM; Chowdhury S; Ferdous J; Hossain F; Begum SR; Jahan M; Tabassum S; Khatun S; Karim AB
Jpn J Clin Oncol; 2012 Jan; 42(1):36-41. PubMed ID: 22194637
[TBL] [Abstract][Full Text] [Related]
31. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial.
Lehtinen M; Apter D; Eriksson T; Harjula K; Hokkanen M; Lehtinen T; Natunen K; Damaso S; Soila M; Bi D; Struyf F
Int J Cancer; 2020 Jul; 147(1):170-174. PubMed ID: 31736068
[TBL] [Abstract][Full Text] [Related]
33. Long-term persistence of immune response to the AS04-adjuvanted HPV-16/18 vaccine in Chinese girls aged 9-17 years: Results from an 8-9-year follow-up phase III open-label study.
Hu Y; Zhang X; He Y; Ma Z; Xie Y; Lu X; Xu Y; Zhang Y; Jiang Y; Xiao H; Struyf F; Folschweiller N; Jiang J; Poncelet S; Karkada N; Jastorff A; Borys D
Asia Pac J Clin Oncol; 2020 Dec; 16(6):392-399. PubMed ID: 32780946
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
[TBL] [Abstract][Full Text] [Related]
35. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2017 Jan; 6(1):12-25. PubMed ID: 27998015
[TBL] [Abstract][Full Text] [Related]
37. Post-approval Safety Monitoring of Quadrivalent and Bivalent Human Papillomavirus Vaccines Based on Real-world Data from the Korea Adverse Events Reporting System (KAERS).
Kim M; Kim S; Shin JY
Clin Drug Investig; 2020 Aug; 40(8):727-735. PubMed ID: 32474825
[TBL] [Abstract][Full Text] [Related]
38. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
39. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
